KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Other Non Operating Income: 2017-2025

Historic Other Non Operating Income for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Sep 2025 value amounting to -$31.4 million.

  • Amneal Pharmaceuticals' Other Non Operating Income fell 1480.83% to -$31.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$16.7 million, marking a year-over-year increase of 54.45%. This contributed to the annual value of $11.8 million for FY2024, which is 128.87% up from last year.
  • According to the latest figures from Q3 2025, Amneal Pharmaceuticals' Other Non Operating Income is -$31.4 million, which was down 480.33% from $8.3 million recorded in Q2 2025.
  • Over the past 5 years, Amneal Pharmaceuticals' Other Non Operating Income peaked at $8.3 million during Q2 2025, and registered a low of -$47.4 million during Q4 2023.
  • Its 3-year average for Other Non Operating Income is -$4.7 million, with a median of $2.3 million in 2024.
  • As far as peak fluctuations go, Amneal Pharmaceuticals' Other Non Operating Income spiked by 935.63% in 2024, and later plummeted by 1,480.83% in 2025.
  • Over the past 5 years, Amneal Pharmaceuticals' Other Non Operating Income (Quarterly) stood at $6.6 million in 2021, then slumped by 44.31% to $3.7 million in 2022, then crashed by 1,383.73% to -$47.4 million in 2023, then surged by 104.58% to $2.2 million in 2024, then plummeted by 1,480.83% to -$31.4 million in 2025.
  • Its Other Non Operating Income stands at -$31.4 million for Q3 2025, versus $8.3 million for Q2 2025 and $4.2 million for Q1 2025.